Literature DB >> 7933249

The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research.

P A Di Sant'Agnese1, A T Cockett.   

Abstract

Endocrine-paracrine (neuroendocrine, amine precursor uptake and decarboxylation [APUD]) cells of the prostato-urethral region are serotonin and peptide containing regulatory cells, which are part of a dispersed neuroendocrine regulatory system also known as the APUD system. These cells most likely regulate growth and differentiation, as well as the secretory functions of the prostate. Prostatic carcinoma exhibits neuroendocrine differentiation in 3 forms: 1) small cell neuroendocrine carcinoma, 2) carcinoid-like tumors and 3) conventional prostatic adenocarcinoma with focal neuroendocrine differentiation. Small cell carcinoma and carcinoid-like tumors are rather rare (1 to 2% of all prostatic malignancies) and generally pursue an aggressive course. Focal neuroendocrine differentiation in adenocarcinoma is extensive in 10% of the cases and may be present in virtually all adenocarcinomas to a minor degree. There are conflicting studies on the prognostic significance of focal neuroendocrine differentiation in prostatic carcinoma, although several suggest a poor prognosis. The finding that serum neuroendocrine markers predict initial insensitivity to or the development of resistance to hormonal suppression therapy, coupled with the recent observation that androgen receptor is not expressed in neoplastic neuroendocrine cells suggests that neuroendocrine differentiation directly results in resistance to hormonal manipulation therapy. Neuroendocrine differentiation in prostatic carcinoma raises the possibility of innovative modes of treatment. Future directions of research should concentrate on the quantitative analysis of serotonin and various peptides in prostatic malignancy, since high levels of constitutive secretion may not be appreciated by immunocytochemistry, as well as analysis of tumors for receptors to neuroendocrine products, which are necessary for these products to have a functional role. Finally, specific subtypes of neoplastic cells with neuroendocrine differentiation based on serotonin and peptide profiles should be analyzed.

Entities:  

Mesh:

Year:  1994        PMID: 7933249     DOI: 10.1016/s0022-5347(17)32417-5

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  15 in total

1.  Characterization of human ribosomal S3a gene expression during adenosine 3':5' cyclic monophosphate induced neuroendocrine differentiation of LNCaP cells. Regulation of S3a gene expression in LNCaP.

Authors:  Jeremy L Goodin; Charles L Rutherford
Journal:  Mol Biol Rep       Date:  2002-09       Impact factor: 2.316

2.  LNCaP prostate cancer cells with autocrine interleukin-6 expression are resistant to IL-6-induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signaling.

Authors:  Dongxia Ge; Allen C Gao; Qiuyang Zhang; Sen Liu; Yun Xue; Zongbing You
Journal:  Prostate       Date:  2011-12-27       Impact factor: 4.104

3.  Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients.

Authors:  J T Wu; M E Astill; G H Liu; R A Stephenson
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

4.  ERG gene rearrangements are common in prostatic small cell carcinomas.

Authors:  Tamara L Lotan; Nilesh S Gupta; Wenle Wang; Antoun Toubaji; Michael C Haffner; Alcides Chaux; Jessica L Hicks; Alan K Meeker; Charles J Bieberich; Angelo M De Marzo; Jonathan I Epstein; George J Netto
Journal:  Mod Pathol       Date:  2011-02-18       Impact factor: 7.842

5.  Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.

Authors:  Hsueh-Li Tan; Akshay Sood; Hameed A Rahimi; Wenle Wang; Nilesh Gupta; Jessica Hicks; Stacy Mosier; Christopher D Gocke; Jonathan I Epstein; George J Netto; Wennuan Liu; William B Isaacs; Angelo M De Marzo; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2013-12-09       Impact factor: 12.531

6.  Rapid progression of mixed neuroendocrine carcinoma-acinar adenocarcinoma of the prostate: A case report.

Authors:  Jingchao Wei; Xiaoping Zheng; Liuxun Li; Wensu Wei; Zhi Long; Leye He
Journal:  Oncol Lett       Date:  2016-06-16       Impact factor: 2.967

7.  Visualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CT.

Authors:  Wolfgang Luboldt; Klaus Zöphel; Gerd Wunderlich; Andrij Abramyuk; Hans-Joachim Luboldt; Joerg Kotzerke
Journal:  Mol Imaging Biol       Date:  2009-05-07       Impact factor: 3.488

8.  Breast and prostate cancer.

Authors:  B K Sharma; A Ray
Journal:  Indian J Clin Biochem       Date:  2000-08

9.  Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas.

Authors:  Harrison Tsai; Carlos L Morais; Mohammed Alshalalfa; Hsueh-Li Tan; Zaid Haddad; Jessica Hicks; Nilesh Gupta; Jonathan I Epstein; George J Netto; William B Isaacs; Jun Luo; Rohit Mehra; Robert L Vessella; R Jeffrey Karnes; Edward M Schaeffer; Elai Davicioni; Angelo M De Marzo; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2015-08-05       Impact factor: 12.531

10.  A useful treatment for patients with advanced mixed-type small cell neuroendocrine carcinoma of the prostate: A case report.

Authors:  Kei-Ichiro Uemura; Go Nakagawa; Katsuaki Chikui; Fukuko Moriya; Makoto Nakiri; Tokumasa Hayashi; Shigetaka Suekane; Kei Matsuoka
Journal:  Oncol Lett       Date:  2013-01-15       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.